On April 21, 2016 Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy company focused on oncology, reported that data from three immuno-oncology studies will be presented at the 2016 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting, which will take place June 3 to June 7, 2016 in Chicago (Press release, Immune Design, APR 21, 2016, View Source [SID:1234511207]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The ASCO (Free ASCO Whitepaper) presentation details are as follows:

Pilot trial of intratumoral (IT) G100, a toll-like receptor-4 (TLR4) agonist, in patients with Merkel cell carcinoma (MCC): Final clinical results and immunologic effects on the tumor microenvironment (TME).

Abstract # 3021

Session Type: Poster Discussion Session
Session Title: Developmental Therapeutics—Immunotherapy

Date: Sunday, June 05
Time: 8 a.m. — 11:30 a.m. (poster session) / 4:45 p.m. — 6 p.m. (poster discussion)
Location: Hall A (poster session) / Hall B1 (poster discussion)
Poster Board: #343

Presenter: Shailender Bhatia, M.D., University of Washington, Fred Hutchinson Cancer Research Center

Using G100 (glucopyranosyl lipid A) to transform the sarcoma tumor immune microenvironment

Abstract #: 11017

Session Type: Poster Discussion Session
Session Title: Sarcoma

Date: Monday, June 6, 2016
Time: 8 a.m. — 11:30 a.m. (poster session) / 3 p.m. — 4:15 p.m. (poster discussion)
Location: Hall A (poster session) / S406 (poster discussion)
Poster Board: 143

Presenter: Seth M. Pollack, M.D., Fred Hutchinson Cancer Research Center

Single-agent LV305 induces anti-tumor immune and clinical responses in patients with advanced or metastatic sarcoma and other cancers expressing NY-ESO-1

Abstract # 3093

Session Type: Poster
Session Title: Developmental Therapeutics—Immunotherapy

Date: Sunday, June 5
Time: 8 a.m. — 11:30 a.m.
Location: Hall A
Poster Board: 415

Presenter: Neeta Somaiah, M.D. Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center

Additional data than those included in the abstracts may be included in the presentations.